NCT01942083TerminatedPhase 1
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 33
- Primary Endpoint
- Safety of OPB-111077
Study Overview
Brief Summary
This is a Phase I, open label, non randomized, multicenter study designed to investigate the safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in subjects with advanced HCC.
Study Design
- Study Type
- Interventional
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histopathologically or clinically diagnosed HCC by Korean Liver Cancer Study Group (KLCSG) guidelines.
- •Subject who has advanced HCC
- •Documented evidence of unresponsiveness to, intolerance to, or ineligibility for sorafenib, or unavailability of appropriate sorafenib treatment
- •Male or female subject, age at consent ≥20 years and ≤75 years.
- •Life expectancy ≥12 weeks.
- •Subjects who agree that they or their partner(s) will practice contraception during the study period and 3 months (12 weeks) after the completion of study treatment.
- •Subjects informed of the diagnosis of advanced HCC who are fully informed about the content of the study by the Investigator using the written consent form, and give written consent to participate in the study of their own free will.
Exclusion Criteria
- •Past liver transplantation
- •Uncontrollable hepatic encephalopathy or ascites
- •Presence of brain metastases
- •Clinically significant gastrointestinal bleeding in past 6 months or current active gastrointestinal bleeding.
- •Primary malignancy other than HCC
- •Human immunodeficiency virus (HIV) infection
- •Severe or poorly controlled complication that may affect the conduct or results of the study.
- •Use of Interferon preparation within 4 weeks (28 days) before start of study treatment in the present study.
- •Pregnant, nursing, or possibly pregnant women, or women desiring to become pregnant during the study period
- •Other cases judged by the Investigator to be ineligible for participation in the study.
Arms & Interventions
OPB-111077
Experimental
orally, once daily
Intervention: OPB-111077 (Drug)
Outcomes
Primary Outcomes
Safety of OPB-111077
Time Frame: Within the first cycle [24 days]
Number of participants with adverse events as assessed by CTCAE v4.0
To investigate the maximum tolerated dose (MTD) of OPB-111077
Time Frame: Within the first cycle [24 days]
• The highest dose that does not lead to discontinuation of dose escalation is defined as the MTD.
Secondary Outcomes
- Pharmacokinetics (PK) properties of OPB-111077 and its metabolites.(Within the first cycle [24 days])
- Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1(Approximately 3-18 weeks depending on tumor response)
- Biomarker of OPB-111077(Within the first cycle [24 days])
Investigators
Similar Trials
Recruiting
Phase 1
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic MalignanciesAdvanced Solid Tumors and Hematologic MalignanciesNCT05690581Beijing InnoCare Pharma Tech Co., Ltd.146
Terminated
Phase 1
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung CancerSmall Cell Lung CarcinomaNCT01187615Bayer9
Completed
Phase 1
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)Nosocomial PneumoniaNCT04223752Merck Sharp & Dohme LLC41
Completed
Phase 1
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentNon-Small-Cell Lung CarcinomaNCT01801111Hoffmann-La Roche138
Recruiting
Phase 1
A Study of HS248 in Patients With Advanced Solid TumorsSolid Tumor, AdultNCT05759234Hanhui Pharmaceutical Co., Ltd24